Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari

▼REZZAYO® (rezafungin) click for GB prescribing information or NI prescribing information

Expert presentations and opinions on Invasive candidiasis

Watch or listen to expert presentations and opinions on invasive candidiasis access dedicated learning resources or materials for your patients

To access efficacy, safety & tolerability of ▼REZZAYO® (rezafungin) as well as efficacy data please click here.

placeholder

What's the importance of early fungal eradication in invasive candidiasis/candidaemia?

Professor Mikulska discusses the importance of early fungal eradication in invasive candidiasis/candidaemia.

VIDEO

UK-RZF-2400040

UK-RZF-2400043 talking heads video

What are the potential benefits of once-weekly REZZAYO® rezafungin in the ward?

Professor Mikulska discusses the potential benefits of once-weekly REZZAYO® rezafungin in the ward?

VIDEO

UK-RZF-2400043

UK-RZF-2400039 - talking head videos

What's the importance of early fungal eradication in invasive candidiasis/candidaemia?

Professor Cornely the potential benefits of once-weekly REZZAYO® rezafungin in the ward.

VIDEO

UK-RZF-2400039

UK-RZF-2400044 - talking head video

What are the challenges of managing DDIs with existing antifungals?

Professor Cornely discusses what the challenges are of managing DDIs with existing antifungals.

VIDEO

UK-RZF-2400044

Talking heads Video

What are the potential benefits of once-weekly REZZAYO® rezafungin for discharge?

Professor Mikulska discusses the potential benefits of once-weekly REZZAYO® rezafungin.

VIDEO

UK-RZF-2400042 

    Adverse events should be reported. Reporting forms and information can be found at http://yellowcard.mhra.gov.uk/.

    Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyUKandROI@mundipharma.com.